From Submission Wave to Strategic Mandate: Why AI in Drug Development Is Here to Stay

There is a question that life sciences executives have been asking for the past three years: is AI in drug development real, or is it another technology cycle that will fade when the results do not match the promises? The answer is now clear. The disruption is real. The data is in. And the regulatory infrastructure to govern it is already being built on both sides of the Atlantic. For US and EU corporations operating in this space, the strategic question is no longer "should we take AI seriously?" It is "how far behind are we, and what does it cost us to stay there?"

This analysis draws on the FDA's official position on AI in drug development. The strategic interpretation and business implications below are original.

The 500+ Submissions No One Is Talking About

Between 2016 and 2023, the FDA's Center for Drug Evaluation and Research reviewed more than 500 drug applications that contained artificial intelligence or machine learning components. This is not a pilot program. This is not early adopters experimenting at the margins. This is a sustained, seven-year wave of AI integration into the drug approval process — and it covers every major phase.

Nonclinical testing. Clinical trials. Postmarketing surveillance. Manufacturing. AI is not entering from one side of the drug lifecycle. It is entering from all directions simultaneously.

So, what this tells us is simple: your competitors — or your clients' competitors — are already inside this system. They are using machine learning to accelerate trial design, predict safety signals, optimize manufacturing yields, and extract signal from real-world patient data. If your organization is still treating AI as a future investment, you are measuring the gap from the wrong starting line.

What the FDA's Draft Guidance Actually Signals

In January 2025, the FDA published draft guidance titled "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products." The title is dry. The implications are not.

Draft guidance from the FDA is the first stage of what eventually becomes a hard regulatory expectation. It represents the agency's current thinking, shaped by years of real submissions, workshops, and external feedback — in this case, over 800 comments from industry, academia, and patient advocacy groups. The content of this guidance was also informed by a public workshop in August 2024.

What the guidance covers matters to any corporation submitting, or planning to submit, AI-generated data to support safety, effectiveness, or quality claims. The FDA is not asking whether you use AI. It is defining the conditions under which that AI-generated information will be considered credible for regulatory purposes.

• Transparency requirements: How the model was developed, validated, and tested must be documented and auditable.
• Risk-based evaluation: The level of scrutiny scales with the impact of the AI output on patient safety decisions.
• Data integrity: The training and validation data must meet standards comparable to traditional trial data governance.
• Ongoing monitoring: For AI models used in postmarketing contexts, lifecycle management expectations now apply.

The thing is, the corporations that engage with this guidance now — before it hardens into binding expectation — are the ones who will shape its final form. Those who wait will inherit whatever the early movers negotiated.

The FDA-EMA Bridge: One AI Strategy for Both Markets

Here is where it gets strategically significant for organizations operating across the Atlantic. The FDA and the European Medicines Agency have jointly published 10 guiding principles for Good AI Practice in Drug Development, released in January 2026. This is not a soft alignment. This is a deliberate signal that the two largest drug regulatory regimes in the world are coordinating their AI frameworks.

For US and EU life sciences corporations, this is both a challenge and an opportunity. The challenge: your AI governance practices now need to satisfy two regulators simultaneously, and the standards are converging. A model validation process designed for FDA submission will increasingly need to satisfy EMA expectations as well, and vice versa.

The opportunity: if you build your AI infrastructure to meet the higher of the two standards from the beginning, you avoid costly retroactive compliance work. You also position yourself to move faster in both markets, because your AI-generated evidence packages will not need to be rebuilt from scratch for each jurisdiction.

This is not a speculative scenario. The FDA and EMA have been building this bridge for three years. The infrastructure is being laid now. Organizations that design their AI programs around the emerging joint standard will have a structural advantage in submission timelines and regulatory credibility.

Where AI Is Already Deciding Outcomes

Machine learning — the core subset of AI driving drug development — is already embedded across the entire product lifecycle. These are not experimental use cases. They are areas where competitive advantage is being built right now.

• Nonclinical development: ML models are predicting toxicity profiles, optimizing dose-response relationships, and reducing the number of animal studies required before moving to human trials.
• Clinical trial design: AI is being used to identify patient populations, predict dropout risk, detect safety signals early, and optimize adaptive trial designs in real time.
• Real-World Data analytics: RWD from electronic health records and claims data is increasingly processed through ML pipelines to generate post-approval evidence — evidence that regulators are starting to accept as supplementary to controlled trial results.
• Digital Health Technologies: AI-driven wearables and digital endpoints are changing how clinical outcomes are measured, and the FDA has published specific frameworks around their use in trials.
• Manufacturing: Process analytical technology powered by ML is improving batch consistency, predicting failures before they occur, and supporting continuous manufacturing models that reduce time-to-market.

Each of these areas represents a competitive lever. The question for your leadership team is which ones are being pulled by your competitors while you are still building the business case.

The CDER AI Council: The Regulator Is Professionalizing Faster Than Most Corporations

In 2024, the FDA established the CDER AI Council — a formal governance body tasked with coordinating all AI activities across the Center for Drug Evaluation and Research. This council consolidates what were previously separate working groups into a single decisional body with oversight over internal AI capabilities, policy development, regulatory consistency, and external communications.

This matters because it tells you something about the pace of institutional change. The regulator has built a dedicated AI governance structure. It has a unified voice. It has a mandate to expand AI use internally — including among non-technical staff — through deliberate education programs.

Now compare that to the state of AI governance in most life sciences corporations. Multiple siloed AI initiatives. No unified submission strategy. No cross-functional AI review process. The regulatory body is, in many cases, better organized around AI than the companies it regulates. That gap creates risk — specifically, submission risk and inspection risk for organizations whose AI practices do not align with what the FDA now expects to see documented.

What This Means for Your Organization

The disruption is not coming. It arrived years ago. What changes now is the formalization — the moment when informal AI adoption becomes regulatory expectation, when pilot programs need to meet the standards of production evidence, and when the quality of your AI governance becomes as important as the quality of your clinical data.

For US and EU life sciences corporations, the practical implications break down into three time horizons:

1. Immediate (0–12 months): Audit your current AI use across the drug lifecycle. Identify which AI components have already entered your submissions — formally or informally — and assess whether they meet the documentation standards emerging from FDA draft guidance.
2. Near-term (12–24 months): Build a unified AI governance framework that satisfies both FDA and EMA principles. Design it once for both markets. Assign ownership for AI model lifecycle management — training, validation, monitoring, and change control.
3. Strategic (24–48 months): Position AI as a core competency in your regulatory submissions, not a supporting tool. Organizations that can demonstrate consistent, auditable AI practices will move through review cycles faster. That is a direct competitive advantage in time-to-market.

Conclusion

AI in life sciences is disruptive — that part is not in dispute. What corporations sometimes miss is that the disruption has already happened. The industry has crossed a threshold. More than 500 AI-containing submissions reviewed. Joint FDA-EMA guidance published. A dedicated AI governance council inside the regulator. Good AI Practice principles aligned across jurisdictions.

The companies that will define the next decade of drug development are the ones treating this disruption not as a threat to manage, but as infrastructure to build. AI is not going anywhere. The only question left for life sciences corporations is how deliberately they choose to get ahead of it.